Gainers
- Aclarion ACON stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million.
- Outset Medical OM shares rose 10.61% to $4.95. The market value of their outstanding shares is at $248.5 million.
- Absci ABSI stock moved upwards by 9.77% to $4.38. The market value of their outstanding shares is at $407.0 million.
- Processa Pharma PCSA shares rose 8.71% to $0.29. The company's market cap stands at $7.0 million.
- Cara Therapeutics CARA stock increased by 7.94% to $0.62. The company's market cap stands at $33.5 million.
- Monopar Therapeutics MNPR shares moved upwards by 6.44% to $0.46. The market value of their outstanding shares is at $6.8 million.
Losers
- Atreca BCEL stock decreased by 21.4% to $0.28 during Friday's after-market session. The market value of their outstanding shares is at $11.0 million.
- Estrella Immunopharma ESLA shares declined by 10.57% to $1.1. The market value of their outstanding shares is at $38.7 million.
- Nektar Therapeutics NKTR stock declined by 6.41% to $0.5. The market value of their outstanding shares is at $95.3 million.
- Brainstorm Cell BCLI shares decreased by 5.17% to $0.31. The company's market cap stands at $15.1 million.
- Context Therapeutics CNTX shares fell 5.05% to $1.13. The company's market cap stands at $18.0 million.
- Revelation Biosciences REVB shares fell 5.03% to $0.45. The company's market cap stands at $2.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ACONAclarion Inc
$0.127010.8%
BCELAtreca Inc Class A
$0.1399-6.73%
BCLIBrainstorm Cell Therapeutics Inc
$2.2910.1%
CARACara Therapeutics Inc
$0.4089-%
CNTXContext Therapeutics Inc
$1.06-2.75%
ESLAEstrella Immunopharma Inc
$1.2311.8%
MNPRMonopar Therapeutics Inc
$25.828.53%
NKTRNektar Therapeutics
$0.98654.84%
OMOutset Medical Inc
$1.05-5.41%
PCSAProcessa Pharmaceuticals Inc
$0.8499-9.85%
REVBRevelation Biosciences Inc
$0.3100-1.46%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in